NUTRITION 21 RETAINS CAMERON ASSOCIATES AS INVESTOR RELATIONS ADVISOR

PURCHASE, N.Y., November 11, 2004 -Nutrition 21, Inc. (NASDAQ: NXXI), the leading developer and marketer of chromium-based nutritional supplements, today announced that it has retained Cameron Associates, Inc. as its investor relations advisor. Cameron Associates is a 28-year-old New York-based, full-service investor relations firm that represents a wide variety of publicly-held companies in the U.S and Canada.

Cameron will assist Nutrition 21, www.nutrition21.com, in broadening its financial market presence and establishing new relationships within the investment community and financial media.

Gail Montgomery, President and Chief Executive Officer of Nutrition 21 commented. "We expect our relationship with Cameron to enhance the visibility and value of the Company as we introduce our products and business strategies to a wider audience.”  Montgomery continued, “I am very pleased with our appointment of Cameron Associates. We believe their experience and knowledge of the investment community and their experience with small public companies, particularly in the healthcare industry, will serve Nutrition 21 and its shareholders well."

Founded in 1976, Cameron Associates, Inc. is a New York City-based, full-service investor relations firm providing strategic counsel to a select group of public companies. Additional information about Cameron Associates can be obtained on the Web at www.cameronassoc.com.

About Nutrition 21:

Nutrition 21 is a biosciences company dedicated to the research, development and commercialization of innovative chromium based products for improved health maintenance and for the prevention and treatment of metabolic diseases such as diabetes, insulin resistance, obesity, depression and cardiovascular disease. Nutrition 21 holds 36 patents for nutrition products, 22 of which are for chromium compounds and their uses. Nutrition 21‘s Chromaxâ, chromium picolinate; a form of the essential mineral chromium was developed by the USDA and is licensed to the Company. It is used as an ingredient in many nutritional supplements. More information is available at http://www.nutrition21.com. www.chromax.com, and www.diachrome.com

Safe Harbor Provision:

This press release may contain certain forward-looking statements.  The words “believe,” “expect,” “anticipate” and other similar expressions generally identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.  These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2004.  Actual results could differ materially from the results referred to in the forward-looking statements.  In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur.  Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.